"However, any open-label study has the potential for an upward bias from patient selection. It’s conceivable that the 40 patients who enrolled in GENR’s Mexican study were cherry picked from the presumably vast pool of eligible individuals in Mexico City."
I fail to see how a cherry picked set of patients would allow patients vision to improve as they did in that study. If they had wet amd, and their vision improved, it was squalamine that did that was reason. Any arguement there?
Market Data 
Markets 
AI
